Cancer prevalence statistics describe how many people were living with a cancer diagnosis during a defined period, rather than how many new cases occurred in a single year. The GLOBOCAN 2022 U.S. and Asia fact sheets report five-year prevalent cases for 2022. These estimates offer a broad view of the number of people and families who may be navigating treatment, recovery, surveillance, or long-term support.
Table of contents
- What five-year prevalence measures
- United States: overall five-year prevalence
- United States: cancer types with the largest counts
- United States: additional cancer types
- Asia: regional cancer prevalence
- Comparing U.S. and Asia figures
- What these figures mean for caregivers
What five-year prevalence measures
Five-year prevalent cases count people who were diagnosed with cancer during the previous five years and were alive at the measurement point. They are not the same as annual incidence, which counts new diagnoses during a particular year. They are also not the same as the total number of people who have ever received a cancer diagnosis.
The figures below are estimates reported in the GLOBOCAN 2022 fact sheets. The U.S. figures refer to the United States, while the regional figures refer to Asia. The measurement year is 2022. The source labels are retained so that readers can distinguish the U.S. and Asia estimates and their different denominators.
For caregivers, prevalence is relevant because it reflects the population living with a recent cancer experience. A five-year count can include people in active treatment as well as people receiving follow-up care or living with ongoing effects. The figures do not identify individual care needs, treatment status, prognosis, or household circumstances.
United States: overall five-year prevalence
The GLOBOCAN 2022 U.S. fact sheet reported 7,845,698 five-year prevalent cases for all cancers in 2022. Of these, 4,082,871 were male five-year prevalent cases and 3,762,827 were female five-year prevalent cases. These sex-specific counts sum to the reported all-cancer total.
The same U.S. fact sheet reported 6,017,588 five-year prevalent cases when non-melanoma skin cancer was excluded. Because the all-cancer and excluding-non-melanoma figures use different case definitions, they should not be treated as interchangeable totals.
The overall U.S. estimate provides scale for caregiver-support planning. It describes millions of people who had a cancer diagnosis within the preceding five years and were alive in 2022. It does not mean that 7,845,698 people required the same kind of help, or that every person was receiving active treatment at the time of measurement.
United States: cancer types with the largest counts
The largest cancer-specific U.S. five-year prevalence figures in the supplied GLOBOCAN 2022 U.S. fact sheet were breast cancer, with 1,194,271 cases, and prostate cancer, with 1,007,844 cases. Colorectal cancer accounted for 552,771 cases, while melanoma accounted for 397,644 cases.
The fact sheet reported 288,303 prevalent lung cancer cases and 281,393 thyroid cancer cases. Bladder cancer accounted for 270,832 cases, and corpus uteri cancer accounted for 253,038 cases. Pancreatic cancer had 214,047 five-year prevalent cases, while non-Hodgkin lymphoma had 206,437.
| U.S. cancer type | Five-year prevalent cases, 2022 |
|---|---|
| Breast cancer | 1,194,271 |
| Prostate cancer | 1,007,844 |
| Colorectal cancer | 552,771 |
| Melanoma | 397,644 |
| Lung cancer | 288,303 |
| Thyroid cancer | 281,393 |
| Bladder cancer | 270,832 |
| Corpus uteri cancer | 253,038 |
| Pancreatic cancer | 214,047 |
| Non-Hodgkin lymphoma | 206,437 |
These counts are cancer-type totals, not a ranking of seriousness or caregiver burden. A larger prevalence count can reflect several factors, including the number of diagnoses and survival over the five-year period. The data supplied here do not quantify treatment intensity, disability, symptoms, or informal caregiving hours.
United States: additional cancer types
The GLOBOCAN 2022 U.S. fact sheet reported 102,458 five-year prevalent cases of liver cancer, 108,877 of ovarian cancer, and 94,302 of oral cavity cancer. Cervical cancer accounted for 68,388 cases. The reported figures for leukemia and multiple myeloma were 54,168 and 54,612, respectively.
Kidney cancer had 53,607 five-year prevalent cases, and laryngeal cancer had 47,857. Brain and central nervous system cancer accounted for 44,624 cases, while Hodgkin lymphoma accounted for 44,064. Vulvar cancer had 36,137 cases, and stomach cancer had 37,331.
The U.S. fact sheet also reported 25,054 five-year prevalent cases for esophageal cancer, 21,568 for penile cancer, and 18,026 for hypopharyngeal cancer. Smaller reported totals included vagina cancer at 4,181 cases, mesothelioma at 3,420, and nasopharyngeal cancer at 6,057.
The variety of these figures matters for caregiver support. A national total combines cancers with different clinical pathways, but the supplied statistics do not provide a breakdown of care requirements by cancer type. They should therefore be used to describe the size and distribution of the recent cancer population, not to predict an individual family’s experience.
Asia: regional cancer prevalence
The GLOBOCAN 2022 Asia fact sheet reported 23,429,909 five-year prevalent cases for all cancers in Asia in 2022. That total represented 43.8% of the global total, according to the same source. The Asia figures below are regional estimates and should not be compared with the U.S. totals as though they represented countries of equal population size.
Among the Asia cancer-specific counts, breast cancer had 3,197,043 five-year prevalent cases, colorectal cancer had 2,784,388, and stomach cancer had 2,075,961. Lung cancer accounted for 1,230,467 cases, while liver cancer accounted for 1,186,812. Cervical cancer had 1,116,947 cases.
The Asia fact sheet reported 833,450 five-year prevalent prostate cancer cases and 710,721 non-Hodgkin lymphoma cases. Bladder cancer had 683,010 cases, pancreatic cancer had 666,780, and kidney cancer had 643,459. Leukemia accounted for 628,694 cases, and oral cavity cancer accounted for 603,826.
Other reported Asia estimates included 538,504 thyroid cancer cases, 504,953 melanoma cases, and 448,321 esophageal cancer cases. Corpus uteri cancer accounted for 213,982 five-year prevalent cases.
The Asia fact sheet also supplied prevalence rates per 100,000 people for several cancer types. Breast cancer was reported at 140.6 per 100,000, colorectal cancer at 59.9, liver cancer at 52.2, cervical cancer at 47.0, and stomach cancer at 44.7. Lung cancer was reported at 26.5 per 100,000, and oral cavity cancer at 26.6.
Additional Asia rates were 22.2 per 100,000 for melanoma, 17.9 for prostate cancer, 15.3 for non-Hodgkin lymphoma, 14.7 for bladder cancer, 14.3 for pancreatic cancer, and 13.8 for kidney cancer. Leukemia was reported at 13.5 per 100,000, thyroid cancer at 11.6, esophageal cancer at 9.6, and corpus uteri cancer at 4.6.
The supplied Asia fact sheet also contains another thyroid cancer row reporting 300,179 five-year prevalent cases and a rate of 6.5 per 100,000 for a different sex/age row. Because that row uses a different subgroup definition from the regional figure of 538,504 cases and 11.6 per 100,000, the two thyroid estimates should not be combined.
Comparing U.S. and Asia figures
The table shows selected five-year prevalence counts and rates reported by the two GLOBOCAN 2022 fact sheets. The U.S. entries shown here are counts; the Asia entries include both counts and rates where the fact sheet supplied them.
| Cancer type | United States cases | Asia cases | Asia rate per 100,000 |
|---|---|---|---|
| Breast | 1,194,271 | 3,197,043 | 140.6 |
| Colorectal | 552,771 | 2,784,388 | 59.9 |
| Lung | 288,303 | 1,230,467 | 26.5 |
| Prostate | 1,007,844 | 833,450 | 17.9 |
| Stomach | 37,331 | 2,075,961 | 44.7 |
| Liver | 102,458 | 1,186,812 | 52.2 |
| Cervical | 68,388 | 1,116,947 | 47.0 |
| Thyroid | 281,393 | 538,504 | 11.6 |
Counts and rates answer different questions. A count describes the estimated number of prevalent cases in the geography. A rate expresses prevalence relative to population size. The table should not be used to infer that one region has greater individual risk from counts alone, and it does not adjust the U.S. figures to the Asia population or vice versa.
What these figures mean for caregivers
Cancer prevalence statistics can help explain why caregiver support needs extend beyond newly diagnosed patients. The U.S. total of 7,845,698 five-year prevalent cases and the Asia total of 23,429,909 show the scale of the population living with a recent cancer diagnosis in 2022. The figures include people at different points in treatment and recovery, so a single total represents varied experiences rather than one standard care pathway.
Cancer-specific counts can also help organizations describe the communities they serve. In the United States, breast and prostate cancer were the two largest reported cancer-specific prevalence groups. In Asia, breast and colorectal cancer had the largest counts among the types listed in the fact sheet. These are population-level patterns, not a substitute for a patient’s clinical information or a caregiver assessment.
The data support careful language: “five-year prevalent cases in 2022,” “reported by the GLOBOCAN 2022 U.S. fact sheet,” and “reported by the GLOBOCAN 2022 Asia fact sheet.” They do not support claims about the number of caregivers, the proportion of patients needing assistance, or the cost of care, because those measurements are not included here.
For families, the most useful interpretation is that prevalence measures the size of the recent cancer population, while individual support needs must be assessed separately. The source figures can frame conversations about service capacity and awareness, but they cannot determine what help a particular person or household will need.